Elite Journal of Medical Sciences. Volume 2 Issue 6(2024), 58-73
https://epjournals.com/journals/EJMS

Oxidative Stress in Sickle Cell Anemia: A Cellular and Molecular Perspective

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

emmanuelobeagu@yahoo.com

Abstract

Sickle Cell Anemia (SCA) is a genetic disorder characterized by the production of abnormal hemoglobin S, leading to chronic oxidative stress and a cascade of pathological events. This review explores oxidative stress from both cellular and molecular perspectives, emphasizing its role in the pathophysiology of SCA. Oxidative stress in SCA arises from elevated reactive oxygen species (ROS) and reactive nitrogen species (RNS), which drive endothelial dysfunction, inflammation, and tissue damage. We delve into the sources of ROS in SCA, including hemolysis, sickling, and inflammatory responses, and examine how these processes contribute to the disease's clinical manifestations. Additionally, the review evaluates current and emerging therapeutic strategies aimed at mitigating oxidative damage, including antioxidant supplements, hydroxyurea, and novel gene therapies. By elucidating the complex interplay between oxidative stress and SCA, this review provides insights into potential therapeutic avenues and future research directions.

Keywords: *Sickle Cell Anemia (SCA), Oxidative Stress, Reactive Oxygen Species (ROS), Reactive Nitrogen Species (RNS), Endothelial Dysfunction, Antioxidant Therapies, Hemolysis*

Introduction

Sickle Cell Anemia (SCA) is a genetic blood disorder characterized by the production of abnormal hemoglobin S (HbS), which leads to the deformation of red blood cells into a sickle shape. This simple genetic mutation has far-reaching consequences, manifesting in a wide array of clinical symptoms that are primarily driven by oxidative stress. Sickle Cell Anemia arises from a single nucleotide mutation in the hemoglobin beta-globin gene, specifically an A to T substitution in the codon for glutamic acid, resulting in the production of valine instead of glutamic acid. This seemingly minor genetic alteration causes hemoglobin molecules to polymerize under low oxygen conditions, leading to the formation of rigid, sickle-shaped red blood cells. These sickled cells are less flexible than normal red blood cells and can obstruct blood flow in the microcirculation, leading to vaso-occlusive crises and tissue damage. This genetic mutation, while straightforward, sets off a cascade of pathological events that are deeply intertwined with oxidative stress. Oxidative stress is a state of imbalance between reactive oxygen species (ROS) and the body's antioxidant defenses. In SCA, oxidative stress is not merely a consequence but a central

pathological mechanism that exacerbates the disease's symptoms. ROS are highly reactive molecules that can damage cellular components, including lipids, proteins, and DNA. In the context of SCA, the sickling process itself is a source of ROS, as the mechanical deformation of red blood cells during sickling can generate free radicals. Furthermore, hemolysis releases free hemoglobin into the bloodstream, where it can contribute to oxidative damage. This imbalance leads to chronic inflammation, endothelial dysfunction, and tissue injury, which are hallmarks of SCA.[1-10]

At the cellular level, oxidative stress affects red blood cells in several critical ways. The sickling of red blood cells leads to increased cell membrane damage and hemolysis. The resulting oxidative damage causes lipid peroxidation, which compromises the integrity of the red blood cell membrane and promotes further sickling. Additionally, oxidative stress damages cellular proteins and nucleic acids, leading to functional impairments and cellular apoptosis. This cellular damage not only exacerbates the direct effects of sickling but also contributes to the chronic inflammation and tissue damage observed in SCA. Reactive oxygen species (ROS) in SCA originate from multiple sources. One significant source is the sickling process itself, which generates oxidative stress through mechanical stress and deformity of red blood cells. Another major source is hemolysis, which releases free hemoglobin into the plasma. Free hemoglobin is broken down into methemoglobin and heme, both of which can catalyze the formation of ROS through Fenton and Haber-Weiss reactions. Additionally, the inflammatory environment in SCA activates leukocytes, which produce ROS as part of the inflammatory response. This continuous production of ROS drives the pathophysiological processes that underlie the disease's clinical manifestations. Endothelial dysfunction is a critical consequence of oxidative stress in SCA. ROS can damage the endothelium, leading to impaired vasodilation and increased expression of adhesion molecules and pro-inflammatory cytokines. This dysfunction promotes vaso-occlusive events and exacerbates the complications of SCA, including pain crises and organ damage. The damaged endothelium also facilitates the adhesion of sickled cells to blood vessel walls, which contributes to the obstructive events seen in SCA. Understanding the mechanisms of endothelial dysfunction provides insight into how oxidative stress drives the disease's progression and highlights potential therapeutic targets.[11-15]

Chronic inflammation is both a consequence and a driver of oxidative stress in SCA. The sickling of red blood cells and subsequent hemolysis lead to the release of inflammatory mediators that perpetuate a state of chronic low-grade inflammation. This inflammatory response generates ROS through activated leukocytes and other inflammatory cells. The resulting oxidative stress further amplifies inflammation and contributes to the progression of SCA. The interplay between oxidative stress and inflammation is a critical aspect of SCA pathophysiology, as it creates a vicious cycle that worsens the disease's symptoms and complications. To combat oxidative stress, cells have developed a range of antioxidant defense mechanisms. These defenses include enzymatic antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase, as well as non-enzymatic antioxidants like vitamin C, vitamin E, and glutathione. In SCA, these defenses are often overwhelmed by the excessive production of ROS. The effectiveness of these antioxidants can be impaired due to the chronic oxidative environment created by sickling and hemolysis. These include antioxidant supplements like vitamin C and E, which neutralize ROS

and reduce oxidative damage. Hydroxyurea, a widely used medication for SCA, not only increases fetal hemoglobin levels but also has direct antioxidant properties. Newer therapies are being explored, including novel antioxidant compounds and gene therapies designed to address the root causes of oxidative stress. These treatments offer hope for improved management of SCA and underscore the importance of continued research in this area.[16-20]

Oxidative Stress in Sickle Cell Anemia

Oxidative stress is a pathological state characterized by an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses. ROS, including free radicals like superoxide anion (O_2^-) and hydroxyl radical (•OH), as well as non-radical species like hydrogen peroxide (H_2O_2), are highly reactive molecules that can cause significant damage to cellular components. Under normal conditions, ROS are produced as byproducts of cellular metabolism, particularly in the mitochondria, but they are usually neutralized by endogenous antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase. However, when ROS production exceeds the capacity of these defense mechanisms, oxidative stress ensues, leading to cellular damage and dysfunction. In Sickle Cell Anemia (SCA), oxidative stress is both a consequence and a driver of disease pathology. The fundamental genetic mutation in SCA, which substitutes valine for glutamic acid in the β-globin chain of hemoglobin, leads to the formation of hemoglobin S (HbS). When deoxygenated, HbS molecules aggregate into long polymers that distort red blood cells into a sickle shape. This sickling process generates mechanical stress on the red blood cell membranes, promoting ROS production. Sickled red blood cells are prone to hemolysis, which releases free hemoglobin into the plasma. Free hemoglobin can be broken down into methemoglobin and heme, each of which further contributes to oxidative stress through Fenton and Haber-Weiss reactions. The primary sources of ROS in SCA are multifaceted and include both intrinsic and extrinsic factors. Intrinsically, the sickling of red blood cells itself generates ROS. The repeated sickling and unsickling cycles cause mechanical stress on cell membranes, which leads to the production of ROS and exacerbates oxidative damage. Additionally, the hemolysis of sickled red blood cells releases free hemoglobin into the bloodstream. In the plasma, free hemoglobin undergoes oxidation to produce methemoglobin and heme, which catalyze the formation of hydroxyl radicals and other ROS through the Fenton reaction.[21-25]

Extrinsic sources of ROS in SCA include the inflammatory response associated with the disease. During vaso-occlusive crises, the activation of leukocytes such as neutrophils and macrophages generates ROS as part of the inflammatory response. These inflammatory cells produce ROS through the respiratory burst, which contributes to further oxidative stress and tissue damage. Additionally, the increased production of ROS from these sources aggravates the oxidative damage seen in SCA. The ROS generated in SCA inflict damage on various cellular components, including lipids, proteins, and nucleic acids. One of the key cellular impacts of oxidative stress is lipid peroxidation. ROS attack polyunsaturated fatty acids in cell membranes, leading to the formation of lipid peroxides. These lipid peroxides cause membrane damage, compromising the integrity of the red blood cell and promoting further sickling. This membrane damage is a central feature of SCA pathophysiology, as it exacerbates the cycle of sickling and hemolysis. Oxidative stress also

leads to protein oxidation, which can affect the structure and function of critical cellular proteins. For example, oxidized hemoglobin S can aggregate more readily, worsening sickling. Proteins involved in redox regulation, signal transduction, and cellular defense mechanisms are also targets of oxidative damage, which can lead to cellular dysfunction and apoptosis. Furthermore, ROS can cause oxidative modifications of DNA, which can lead to mutations and contribute to the progression of SCA-related complications. The oxidative stress experienced by red blood cells in SCA has several dire consequences for their function. The sickling of red blood cells impairs their ability to transport oxygen efficiently, leading to tissue hypoxia. Additionally, oxidative stress-induced membrane damage weakens red blood cells, making them more susceptible to hemolysis. The release of free hemoglobin during hemolysis not only further generates ROS but also depletes nitric oxide (NO), a molecule crucial for vascular health. NO depletion contributes to endothelial dysfunction and exacerbates the vaso-occlusive episodes characteristic of SCA.[26-30]

Beyond its effects on red blood cells, oxidative stress in SCA has systemic implications. The chronic inflammation driven by oxidative stress leads to the production of pro-inflammatory cytokines and adhesion molecules. These factors contribute to endothelial dysfunction, which manifests as increased blood vessel inflammation and permeability. Endothelial dysfunction further promotes the adhesion of sickled red blood cells to the vessel walls, exacerbating vaso-occlusive crises and leading to pain and organ damage. Moreover, systemic oxidative stress affects various organs and tissues, leading to complications such as stroke, acute chest syndrome, and organ failure. The cumulative damage from oxidative stress and inflammation can significantly reduce the quality of life for individuals with SCA and increase their risk of severe health outcomes. To combat the oxidative stress caused by SCA, the body relies on an intricate antioxidant defense system. Enzymatic antioxidants like SOD, catalase, and glutathione peroxidase neutralize ROS, while non-enzymatic antioxidants such as vitamin C, vitamin E, and glutathione provide additional protection against oxidative damage. However, in SCA, this antioxidant defense system is often overwhelmed by the excessive ROS generated from sickling, hemolysis, and inflammation. The effectiveness of these antioxidant defenses can be further compromised by the disease's chronic oxidative environment. To address oxidative stress in SCA, several therapeutic strategies have been explored. Antioxidant supplements, such as vitamin C and vitamin E, are used to bolster the body’s natural defenses against ROS. Hydroxyurea, a common treatment for SCA, increases the levels of fetal hemoglobin and has direct antioxidant effects. New therapeutic approaches are also under investigation, including novel antioxidant compounds and gene therapies designed to correct the genetic mutation and restore redox balance. These strategies offer hope for reducing oxidative stress and improving outcomes for individuals with SCA.[31-40]

Sources of Reactive Oxygen Species (ROS) in SCA

The sickling of red blood cells is the most direct source of ROS in Sickle Cell Anemia (SCA). The genetic mutation in the β-globin gene of hemoglobin leads to the production of hemoglobin S (HbS), which under low oxygen conditions polymerizes to form long, rigid fibers. These fibers deform red blood cells into a sickle shape. The sickling process involves the repeated deformation of red blood cells, which generates mechanical stress on the cell membrane. This stress causes lipid peroxidation, a process where ROS attack and degrade membrane lipids, leading to increased

production of secondary ROS and further cellular damage. Sickled cells expose HbS to the extracellular environment, where it can undergo oxidation reactions. This process generates ROS, including superoxide anion (O_2^-), which can initiate a cascade of oxidative damage within the cell. Hemolysis, the destruction of red blood cells, is a common occurrence in SCA and a significant source of ROS. When sickled red blood cells rupture, they release free hemoglobin into the plasma. Free hemoglobin is broken down into methemoglobin and heme. Heme acts as a pro-oxidant molecule, catalyzing the formation of ROS through Fenton and Haber-Weiss reactions. The heme catalyzes the conversion of hydrogen peroxide (H_2O_2) into highly reactive hydroxyl radicals (•OH), which cause oxidative damage to cellular components. Free hemoglobin scavenges nitric oxide (NO), a molecule that protects endothelial cells from oxidative damage. The depletion of NO leads to increased vascular inflammation and endothelial dysfunction, further promoting oxidative stress. Activated neutrophils and macrophages undergo a respiratory burst, during which they produce superoxide anions (O_2^-) and other ROS through the enzyme NADPH oxidase. These ROS contribute to inflammation and tissue damage. The inflammatory environment in SCA is characterized by the release of pro-inflammatory cytokines and chemokines, which further stimulate ROS production and perpetuate the cycle of oxidative stress.[41-45]

The mitochondria are a primary source of ROS under normal conditions due to the leakage of electrons from the electron transport chain, which reacts with oxygen to form superoxide anions. In SCA, increased oxidative stress from sickling and hemolysis exacerbates mitochondrial damage, leading to increased ROS production. Mitochondrial dysfunction in SCA also impairs the cell's ability to manage oxidative stress. Damage to mitochondrial DNA, proteins, and lipids can lead to further increases in ROS levels. Sickled cells adhere to endothelial cells and release pro-inflammatory cytokines, which stimulate endothelial cells to produce ROS. This activation contributes to endothelial dysfunction, a key feature of SCA pathology. The ROS produced from the sickled cells and activated endothelium can diffuse into vascular smooth muscle cells, causing oxidative damage and contributing to vascular remodeling and dysfunction. Chronic oxidative stress depletes key antioxidants such as glutathione, vitamin C, and vitamin E. The reduction in these antioxidants impairs the cell’s ability to neutralize ROS, leading to further oxidative damage. ROS can also impair the activity of antioxidant enzymes like superoxide dismutase (SOD) and catalase. The reduced activity of these enzymes exacerbates oxidative stress and contributes to disease progression. Iron in the body can participate in the Fenton reaction, which generates hydroxyl radicals (•OH) from hydrogen peroxide (H_2O_2). This reaction exacerbates oxidative damage to cellular components. Excess iron can promote ROS formation and contribute to oxidative damage in various tissues, including the heart, liver, and endocrine organs.[46-50]

Mutations in the hemoglobin gene can alter redox balance, affecting the stability and function of hemoglobin. This destabilization can lead to increased ROS production and oxidative stress. Genetic variations in genes encoding antioxidant enzymes may affect the efficiency of oxidative stress responses in individuals with SCA. Exposure to environmental pollutants and toxins can increase ROS production and exacerbate oxidative stress. SCA patients may experience heightened vulnerability to these stressors due to their already compromised oxidative balance. Lifestyle choices such as diet, smoking, and alcohol consumption can influence oxidative stress levels. A diet lacking in antioxidants or high in pro-oxidant substances can exacerbate oxidative

stress in SCA patients. Conditions such as diabetes, hypertension, and cardiovascular diseases can interact with SCA to worsen oxidative stress. For example, diabetes can enhance ROS production and oxidative damage through hyperglycemia and inflammation.[51-52]

Cellular Mechanisms of Oxidative Stress in SCA

Lipid peroxidation is a major consequence of oxidative stress in Sickle Cell Anemia (SCA) and plays a central role in the pathophysiology of the disease. ROS, particularly hydroxyl radicals (•OH) and superoxide anions (O_2^-), attack polyunsaturated fatty acids in cellular membranes, initiating a cascade of lipid peroxidation. This process results in the formation of lipid peroxides, which decompose into aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). Lipid peroxidation compromises the integrity of red blood cell membranes, leading to increased cell fragility. The damaged membranes exacerbate the sickling process by promoting further membrane destabilization and the release of hemoglobin and other intracellular components. Lipid peroxidation products like MDA and 4-HNE are highly reactive and can modify cellular proteins, lipids, and DNA. These modifications can trigger inflammatory responses and perpetuate oxidative damage. Protein oxidation is another significant effect of oxidative stress in SCA. ROS can oxidize amino acid residues in proteins, leading to alterations in protein structure and function. In SCA, ROS-induced oxidation of hemoglobin S (HbS) can exacerbate sickling. Oxidative modifications can promote further aggregation of HbS molecules, increasing red blood cell deformability and sickling. Oxidation of proteins can impair the function of key enzymes involved in cellular metabolism and redox balance. For example, ROS-induced oxidation of superoxide dismutase (SOD) and catalase impairs their ability to neutralize ROS, leading to increased oxidative damage. Oxidatively damaged proteins are often targeted for degradation by the proteasome or autophagic pathways. However, excessive protein oxidation can overwhelm these systems, leading to the accumulation of damaged proteins and cellular dysfunction.[53-57]

ROS can cause oxidative modifications to DNA bases, such as 8-oxoguanine, which can lead to mutations during DNA replication. These mutations can contribute to cellular dysfunction and disease progression. ROS-induced DNA damage can result in single- and double-strand breaks. Persistent DNA damage activates repair mechanisms, but failure or inefficiency in repair can lead to genomic instability and contribute to the pathogenesis of SCA. Chronic oxidative stress depletes key antioxidants such as glutathione, vitamin C, and vitamin E. Glutathione, in particular, is crucial for neutralizing ROS and maintaining cellular redox balance. Its depletion exacerbates oxidative damage and impairs cellular defense mechanisms. ROS can oxidize and inactivate antioxidant enzymes like SOD, catalase, and glutathione peroxidase. The dysfunction of these enzymes reduces the cell's ability to manage oxidative stress and increases susceptibility to further ROS damage. Mitochondria are a primary site for ROS production due to electron leakage in the electron transport chain. In SCA, increased ROS from other sources exacerbates mitochondrial damage, creating a vicious cycle of oxidative stress. ROS-induced damage to mitochondrial DNA impairs mitochondrial function and contributes to a decline in ATP production and increased ROS generation. This dysfunction can further exacerbate the effects of oxidative stress. During vaso-occlusive crises, activated leukocytes produce ROS through the NADPH oxidase complex. These

ROS contribute to tissue damage and amplify the inflammatory response. Inflammatory cytokines such as TNF-α and IL-1β promote ROS production and exacerbate oxidative stress. The release of these cytokines can lead to endothelial dysfunction and vascular damage.[58-62]

Free hemoglobin released during hemolysis scavenges NO, reducing its availability for endothelial cells. NO is crucial for maintaining vascular tone and inhibiting platelet aggregation, so its depletion contributes to endothelial dysfunction and vascular complications in SCA. The reduction in NO levels leads to increased oxidative stress on endothelial cells, resulting in damage to the vascular endothelium and promoting conditions such as vasculopathy and organ damage. ROS-induced damage to vascular smooth muscle cells can lead to alterations in cell function and structure. This damage affects vascular tone and contributes to the pathogenesis of vaso-occlusive events in SCA. ROS can activate pro-inflammatory signaling pathways in vascular smooth muscle cells, contributing to chronic inflammation and vascular damage. Chronic oxidative stress can damage hematopoietic stem cells, affecting their ability to produce healthy red blood cells. This damage can contribute to the pathogenesis of SCA and the progression of the disease. Treatments that enhance antioxidant defenses, such as vitamin C, vitamin E, and glutathione supplementation, are being explored to mitigate oxidative stress in SCA. Emerging approaches such as gene therapy aim to correct the genetic mutation causing SCA or enhance the expression of antioxidant proteins to reduce oxidative stress.[63-65]

Molecular Consequences of Oxidative Stress in SCA

One of the most direct molecular consequences of oxidative stress in Sickle Cell Anemia (SCA) is the modification of hemoglobin S (HbS), the pathological form of hemoglobin responsible for the disease. ROS can oxidize specific sites on HbS, such as the heme group and amino acid residues. This oxidation can lead to the formation of methemoglobin and other oxidized forms of hemoglobin that are less efficient in oxygen transport and more prone to sickling. Oxidative modifications to HbS promote the polymerization of hemoglobin molecules into long, rigid fibers under low oxygen conditions. This polymerization causes the sickling of red blood cells, which leads to vaso-occlusive crises and hemolysis. Oxidative stress can decrease the oxygen affinity of HbS, exacerbating the sickling process. The lower oxygen affinity increases the likelihood of HbS polymerization and red blood cell deformation. Oxidative stress causes widespread protein oxidation in SCA, impacting numerous cellular proteins and leading to functional impairments. ROS-induced oxidation leads to the formation of protein carbonyls, a hallmark of protein damage. Carbonylated proteins often lose their normal function and may aggregate, which contributes to cellular dysfunction and disease pathology. Key enzymes, including antioxidant enzymes (SOD, catalase) and metabolic enzymes (glycolytic enzymes), are inactivated by oxidative modifications. For instance, oxidative stress reduces the activity of SOD, impairing the conversion of superoxide anions (O_2^-) to hydrogen peroxide (H_2O_2) and exacerbating oxidative damage. Protein oxidation can alter cellular signaling pathways. For example, oxidation of signaling proteins can disrupt pathways involved in cell growth, apoptosis, and stress responses, leading to exacerbation of the disease.[66-70]

Oxidative stress leads to significant DNA damage in SCA, which can result in genetic mutations and contribute to disease progression. One of the major oxidative DNA lesions is 8-oxoguanine, which can mispair during DNA replication, leading to G to T transversions. This mutagenic effect can contribute to genetic instability and the progression of SCA. ROS can induce single- and double-strand breaks in DNA. These breaks can lead to chromosomal abnormalities and genomic instability, which can exacerbate the effects of oxidative stress and promote disease severity. Oxidative stress leads to lipid peroxidation, which has several molecular consequences for cell membranes and other lipid-rich structures. ROS attack polyunsaturated fatty acids in cell membranes, leading to the formation of lipid peroxides. These peroxides decompose into reactive aldehydes, such as MDA and 4-HNE, which can further damage cellular components. Lipid peroxidation compromises membrane integrity, leading to increased red blood cell hemolysis and the release of hemoglobin into the plasma, which contributes to oxidative stress and vascular complications. Oxidative stress in SCA disrupts the balance of antioxidant defenses, leading to a decreased ability to manage ROS levels. Glutathione is a crucial antioxidant that neutralizes ROS. In SCA, oxidative stress depletes glutathione levels, reducing the cell's capacity to detoxify ROS and exacerbating oxidative damage. ROS can modify and inactivate antioxidant enzymes such as SOD, catalase, and glutathione peroxidase. This inactivation impairs the cell's ability to neutralize ROS and maintain redox balance.[71-72]

Oxidative stress in SCA triggers inflammatory responses through various signaling pathways and mediators. ROS activate the NF-κB signaling pathway, which leads to the transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. These cytokines contribute to the inflammatory milieu in SCA and exacerbate disease symptoms. ROS induce endothelial cell activation, leading to the expression of adhesion molecules and pro-inflammatory cytokines. This endothelial dysfunction contributes to vascular inflammation and the development of vaso-occlusive crises. Oxidative stress leads to mitochondrial DNA damage, which impacts mitochondrial function and cellular energy metabolism. ROS cause mutations in mitochondrial DNA, which can impair mitochondrial function and increase ROS production. This damage affects ATP synthesis and contributes to the pathophysiology of SCA. Oxidative stress can lead to mitochondrial dysfunction, characterized by decreased ATP production, increased ROS generation, and impaired cellular energy metabolism. This dysfunction exacerbates oxidative damage and disease symptoms. Oxidative stress leads to the depletion of nitric oxide (NO), a crucial signaling molecule for vascular health. Free hemoglobin released from hemolyzed red blood cells scavenges NO, reducing its availability. NO is essential for vasodilation, and its depletion leads to endothelial dysfunction and increased vasoconstriction. The reduction of NO affects vascular tone and contributes to the development of vaso-occlusive crises and other vascular complications in SCA. Oxidative stress affects cellular redox signaling pathways, which are crucial for maintaining cellular homeostasis. ROS influence the activity of redox-sensitive transcription factors such as Nrf2 (nuclear factor erythroid 2-related factor 2), which regulates antioxidant defense genes. Dysregulation of Nrf2 can impair the cellular response to oxidative stress. ROS can induce apoptosis through the activation of pro-apoptotic pathways. Excessive oxidative stress triggers apoptosis in red blood cells and other cell types, contributing to the progression of SCA.[72-73]

Antioxidant Defenses in SCA

Antioxidant defenses play a critical role in maintaining redox balance and protecting cells from oxidative damage in Sickle Cell Anemia (SCA). These defenses include enzymatic and non-enzymatic antioxidants that work synergistically to neutralize reactive oxygen species (ROS) and maintain cellular homeostasis. Key enzymatic antioxidants include superoxide dismutase (SOD), catalase, and glutathione peroxidase. These enzymes catalyze the breakdown of superoxide radicals (O_2^-), hydrogen peroxide (H_2O_2), and lipid peroxides, respectively, into less harmful molecules. Non-enzymatic antioxidants include molecules such as glutathione (GSH), vitamins C and E, and beta-carotene. These antioxidants scavenge free radicals directly or regenerate other antioxidants, playing a crucial role in protecting cellular components from oxidative damage. Glutathione is a pivotal non-enzymatic antioxidant in SCA, critical for maintaining cellular redox balance and protecting against oxidative stress. Glutathione directly scavenges ROS such as hydrogen peroxide (H_2O_2) and lipid peroxides, reducing them to less harmful compounds. Glutathione also serves as a cofactor for glutathione peroxidase, which reduces lipid peroxides to lipid alcohols and hydrogen peroxide to water, thereby detoxifying ROS and protecting cellular structures from oxidative damage. Glutathione disulfide (GSSG), the oxidized form of glutathione, is regenerated to GSH by glutathione reductase using NADPH as a reducing equivalent, ensuring a continuous supply of reduced glutathione for antioxidant defense.[71-73]

Vitamins C and E are essential non-enzymatic antioxidants that contribute significantly to the antioxidant defenses in SCA. Ascorbic acid scavenges ROS directly and regenerates vitamin E, enhancing its antioxidant properties. Vitamin C also plays a role in maintaining the reduced form of glutathione, further supporting antioxidant defenses. Vitamin E is a lipid-soluble antioxidant that protects cell membranes from oxidative damage by scavenging lipid peroxyl radicals. It prevents the propagation of lipid peroxidation reactions, thereby preserving membrane integrity and function. Enzymatic antioxidants such as catalase and superoxide dismutase (SOD) play critical roles in detoxifying ROS and protecting cells from oxidative stress. Catalase catalyzes the breakdown of hydrogen peroxide (H_2O_2) into water and oxygen, preventing the formation of hydroxyl radicals (•OH) through the Fenton reaction. This enzyme is particularly important in erythrocytes, where it protects against oxidative damage induced by hemoglobin autoxidation. **Superoxide Dismutase (SOD)** converts superoxide radicals (O_2^-) into hydrogen peroxide (H_2O_2), which can then be further detoxified by catalase or glutathione peroxidase. SOD is crucial for preventing the accumulation of superoxide radicals and minimizing oxidative damage to cellular components. In response to chronic oxidative stress in SCA, cells activate adaptive antioxidant responses to enhance their defense mechanisms. The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is a key regulator of antioxidant and detoxification genes. Under oxidative stress conditions, Nrf2 is activated and translocates to the nucleus, where it induces the expression of antioxidant enzymes (e.g., SOD, catalase) and phase II detoxification enzymes (e.g., glutathione S-transferase). Heat shock proteins are induced in response to oxidative stress and act as molecular chaperones to stabilize proteins and facilitate their refolding or degradation under stress conditions. **Heat Shock Proteins (HSPs)** play a critical role in protecting cells from oxidative damage-induced protein misfolding and aggregation. Enhancing antioxidant defenses represents a promising therapeutic approach for managing oxidative stress and improving clinical

outcomes in SCA. Supplementation with antioxidants such as vitamins C and E, and N-acetylcysteine (a precursor to glutathione), aims to bolster cellular antioxidant defenses and reduce oxidative damage. Hydroxyurea, a disease-modifying therapy for SCA, increases fetal hemoglobin (HbF) levels and induces the expression of antioxidant enzymes like SOD. This mechanism contributes to its beneficial effects in reducing oxidative stress and improving disease severity.[65-70]

Therapeutic Strategies Targeting Oxidative Stress in SCA

One of the primary approaches to managing oxidative stress in Sickle Cell Anemia (SCA) is through the supplementation of antioxidants to enhance the body's natural defenses against reactive oxygen species (ROS). These vitamins are potent antioxidants that can be used to neutralize ROS and reduce oxidative damage. Vitamin C (ascorbic acid) acts as a reducing agent, regenerating other antioxidants and directly scavenging ROS. Vitamin E (α-tocopherol) protects cell membranes from lipid peroxidation. Clinical trials have explored their efficacy in SCA, with mixed results. **N-Acetylcysteine (NAC)** serves as a precursor to glutathione, a critical antioxidant in cells. By increasing glutathione levels, NAC can enhance the cell's ability to neutralize ROS. Hydroxyurea is a well-established disease-modifying therapy for SCA that exerts its effects through multiple mechanisms, including the reduction of oxidative stress. Hydroxyurea increases the production of fetal hemoglobin (HbF), which inhibits the polymerization of hemoglobin S (HbS) and reduces red blood cell sickling. Additionally, hydroxyurea upregulates the expression of antioxidant enzymes, such as superoxide dismutase (SOD) and catalase, which helps to counteract oxidative stress. The clinical efficacy of hydroxyurea in managing oxidative stress and improving SCA outcomes is well-documented. L-arginine is an amino acid that serves as a substrate for nitric oxide (NO) synthase, leading to increased NO production, which has antioxidant properties. L-arginine supplementation increases NO levels, which can enhance vasodilation and improve blood flow. NO also reacts with superoxide radicals to form peroxynitrite, which can mitigate some of the oxidative damage.[71-72]

Combining hydroxyurea with L-arginine is a therapeutic strategy that leverages their complementary mechanisms to combat oxidative stress and improve clinical outcomes. Hydroxyurea reduces oxidative stress by increasing antioxidant defenses and HbF levels, while L-arginine enhances NO production, which has antioxidant effects. Combined therapy aims to address multiple aspects of oxidative stress and SCA pathology. Advances in gene therapy offer promising avenues for targeting oxidative stress at the genetic level in SCA. Techniques such as CRISPR/Cas9 are being explored to correct the genetic mutation responsible for SCA or to modify the expression of genes involved in oxidative stress pathways. Pharmacological agents that target specific redox pathways offer additional strategies for managing oxidative stress in SCA. Roxadustat, a **Hypoxia-Inducible Factor (HIF)** stabilizer, is being studied for its potential to increase endogenous antioxidant responses and improve anemia in SCA. Since oxidative stress and inflammation are closely linked in SCA, anti-inflammatory agents can be used to indirectly reduce oxidative stress. **Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)** reduce inflammation and may indirectly alleviate oxidative stress. However, their use is often limited by side effects and their variable impact on oxidative stress in SCA. Newer anti-inflammatory agents,

such as those targeting specific inflammatory cytokines (e.g., TNF-α inhibitors), are being investigated for their potential to reduce oxidative stress and inflammation in SCA. Dietary and lifestyle modifications can support antioxidant defenses and overall health in SCA patients. Diets rich in fruits, vegetables, and whole grains provide natural sources of antioxidants and other nutrients that can support redox balance. Moderate physical exercise has been shown to enhance antioxidant defenses and reduce oxidative stress.[70-74]

Conclusion

Oxidative stress plays a central role in the pathophysiology of Sickle Cell Anemia (SCA), influencing both disease progression and clinical outcomes. The imbalance between reactive oxygen species (ROS) and antioxidant defenses in SCA contributes to a cascade of cellular and molecular events that exacerbate the symptoms of the disease. ROS, including superoxide radicals, hydrogen peroxide, and hydroxyl radicals, inflict oxidative damage on cellular components such as lipids, proteins, and DNA. This oxidative damage underlies many of the clinical manifestations of SCA, including hemolysis, endothelial dysfunction, and vaso-occlusive crises.

Redox homeostasis is crucial for maintaining cellular health, and its disruption in SCA highlights the need for effective antioxidant strategies. Antioxidant defenses, including enzymatic antioxidants like superoxide dismutase (SOD) and catalase, as well as non-enzymatic antioxidants such as glutathione, vitamins C and E, are vital in counteracting oxidative stress. However, in SCA, these defenses are often overwhelmed, leading to increased oxidative damage and exacerbation of disease symptoms. Therapeutic approaches such as antioxidant supplementation, hydroxyurea therapy, and L-arginine supplementation have shown potential in addressing oxidative stress and improving patient outcomes.

References

1. Ata F, Rahhal A, Malkawi L, Iqbal P, Khamees I, Alhiyari M, Yousaf Z, Qasim H, Alshurafa A, Sardar S, Javed S. Genotypic and phenotypic composition of sickle cell disease in the Arab population-a systematic review. Pharmacogenomics and Personalized Medicine. 2023:133-144.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75

7. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
8. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
9. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
10. Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ, CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. American journal of hematology. 2011;86(6):484-849.
11. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-2487.
12. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
13. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
14. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
15. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
16. Wang Q, Zennadi R. The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications. Antioxidants. 2021;10(10):1608.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants in the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord, 2018; 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).

25. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
26. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
27. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
28. Hernansanz-Agustín P, Enríquez JA. Generation of reactive oxygen species by mitochondria. Antioxidants. 2021;10(3):415.
29. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
30. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
31. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
32. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
33. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
34. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
35. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
36. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
37. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
38. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
39. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024;103(6):e37127.

40. Orrico F, Laurance S, Lopez AC, Lefevre SD, Thomson L, Möller MN, Ostuni MA. Oxidative stress in healthy and pathological red blood cells. Biomolecules. 2023;13(8):1262.
41. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
42. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
43. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
44. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
45. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
46. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
47. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
48. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
49. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
50. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
51. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
52. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine (Baltimore). 2024 ;103(2):e36898. doi: 10.1097/MD.0000000000036898. PMID: 38215146; PMCID: PMC10783340.
54. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. Ann Med Surg (Lond). 2024;86(3):1570-1574. doi: 10.1097/MS9.0000000000001763. PMID: 38463100; PMCID: PMC10923353.
55. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. Medicine (Baltimore). 2024;103(20):e38164. doi: 10.1097/MD.0000000000038164. PMID: 38758879; PMCID: PMC11098235.
56. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches. Medicine (Baltimore). 2024;103(17):e37941. doi: 10.1097/MD.0000000000037941. PMID: 38669382; PMCID: PMC11049766.

57. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine (Baltimore). 2023;102(48):e36462. doi: 10.1097/MD.0000000000036462. PMID: 38050205; PMCID: PMC10695528.
58. Dilli PP, Obeagu E, Tamale A, Ajugwo A, Pius T, Makeri D. Update on the practice of premarital screening for sickle cell traits in Africa: a systematic review and meta-analysis. BMC Public Health. 2024 May 31;24(1):1467. doi: 10.1186/s12889-024-19001-y. PMID: 38822327; PMCID: PMC11143629.
59. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: Diarrhea in sickle cell anemia. Medicine (Baltimore). 2024;103(18):e38075. doi: 10.1097/MD.0000000000038075. PMID: 38701274; PMCID: PMC11062666.
60. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine (Baltimore). 2024;103(6):e37127. doi: 10.1097/MD.0000000000037127. PMID: 38335412; PMCID: PMC10860944.
61. Obeagu EI. Eosinophilic dialogues: A molecular exploration of sickle cell anemia severity. Annals of Medicine and Surgery. 2024:10-97.
62. Pisoschi AM, Pop A, Iordache F, Stanca L, Predoi G, Serban AI. Oxidative stress mitigation by antioxidants-an overview on their chemistry and influences on health status. European Journal of Medicinal Chemistry. 2021; 209:112891.
63. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacology & therapeutics. 2014;141(2):150-159.
64. Park SH, Bao G. CRISPR/Cas9 gene editing for curing sickle cell disease. Transfusion and Apheresis Science. 2021;60(1):103060.
65. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric blood & cancer. 2012;59(2):365-371.
66. Sadaf A, Quinn CT. L-glutamine for sickle cell disease: Knight or pawn? Experimental Biology and Medicine. 2020;245(2):146-54.
67. Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematology/Oncology Clinics. 2016;30(3):591-608.
68. Leonard A, Tisdale J, Abraham A. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? British journal of haematology. 2020;189(3):408-423.
69. Silva DG, Junior EB, De Almeida EA, Bonini-Domingos CR. Oxidative stress in sickle cell disease: an overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies. Free Radical Biology and Medicine. 2013; 65:1101-1109.
70. Ahmed SG, Ibrahim UA. A compendium of pathophysiologic basis of etiologic risk factors for painful vaso-occlusive crisis in sickle cell disease. Nigerian Journal of Basic and Clinical Sciences. 2017;14(2):57-77.
71. Lakkakula BV, Sahoo R, Verma H, Lakkakula S. Pain management issues as part of the comprehensive care of patients with sickle cell disease. Pain Management Nursing. 2018;19(6):558-572.

72. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. Journal of Hematology & Oncology. 2022;15(1):20.
73. Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood, The Journal of the American Society of Hematology. 2016;127(7):839-848.